Piramal Pharma (PPLPHARMA)

FairStock Score: 25/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Free cash flow is positive at ₹404 Cr despite accounting losses, showing some cash generation.
• Debt-to-equity of 0.60 is moderate, so the balance sheet is not excessively leveraged.
• Latest quarter revenue of ₹2,140 Cr and a 5-year revenue CAGR of 7.7% indicate meaningful operating scale.
• ROCE of 6.45% is positive, even though ROE is negative due to current losses.

Concerns

• Worsening losses: net profit fell -3,241% and ROE is -2.01%, with latest quarterly loss of ₹136 Cr.
• Valuation is rich: P/B of 2.68 and EV/EBITDA of 242.98 for a loss-making business.
• Sales growth is weak at -0.87%, and the 5-year CAGR of 7.7% is modest for pharma.
• Altman Z-Score of 2.12 sits in a cautionary zone, and promoter holding of 34.85% is not very high.

AI Analysis

Let me look at Piramal Pharma through the lens I have used for decades. A business must first earn decent returns on capital; here, return on equity is -2.01%, return on capital employed is only 6.45%, and the latest quarter delivered a net loss of ₹136 Cr on sales of ₹2,140 Cr. Profit growth of -3,241% tells me the losses are getting worse, not better. I cannot value a company with no P/E and an EV/EBITDA of 242.98; that is a price that assumes perfection. The stated DCF value is absurd—I would discard it rather than rely on it. Book value is ₹61.13, yet shares trade at ₹163.80, a P/B of 2.68. Paying nearly 2.7 times book for a business destroying shareholder value is not my idea of a margin of safety. Revenue is essentially flat, -0.87% most recently, and even the five-year CAGR of 7.7% is modest for pharmaceuticals. The balance sheet is not catastrophic: debt/equity at 0.60 and positive free cash flow of ₹404 Cr mean the company is not drowning. The Altman Z-score of 2.12, however, keeps me cautious. I also note promoter holding of only 34.85%; in India, I prefer owners who have more skin in the game. This has some attributes of a turnaround—cash flow is positive, and there is a viable operating franchise—but the earnings trend and valuation give no reason to act today. In Graham's words, price is what you pay; value is what you get. Right now, I don't see enough value to offset the risks. I will wait until profitability and returns on capital show sustained improvement.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer